The switching report
Fisetin's dose problem is quietly reshaping how it is sold
The senolytic story is built on mouse data and a handful of human trials. The bigger obstacle for buyers is that most capsules cannot deliver a meaningful dose.
Fisetin is a flavonoid found in strawberries, and it is sold as a senolytic: something that clears senescent cells. The mechanism is plausible and the animal data is genuinely interesting. The delivery problem is where most of the argument now sits.
The short version
- Fisetin extended median and maximum lifespan in aged mice in the Interventions Testing Program. No human trial has measured a longevity endpoint.
- Oral bioavailability is commonly cited below ten percent, which makes standard capsule doses hard to reconcile with the concentrations used in research.
- Formats claiming enhanced absorption, liposomal and phospholipid complexes among them, are now the main competitive axis in this category.
- Senolytic effects, if real, are slow and silent. Nobody should expect to feel anything.
The mechanism, briefly
Senescent cells stop dividing but do not die. They accumulate with age and secrete inflammatory signals, a pattern usually referred to as the senescence-associated secretory phenotype. Senolytics are compounds that push those cells into apoptosis while leaving healthy cells alone.
Fisetin appears to do this by interfering with survival pathways that senescent cells depend on, including PI3K and AKT signalling and the Bcl-2 family. That is a coherent story and it is well supported in cell and animal work.
Where the human evidence stops
The most cited result comes from the Interventions Testing Program at the Jackson Laboratory, where fisetin supplementation extended both median and maximum lifespan in aged mice. That is a meaningful finding in a rigorous programme, and it is still a mouse finding.
Human trials exist but they are small and they measure surrogate endpoints. Nothing so far establishes that intermittent fisetin dosing clears senescent cells in people at a scale that changes how they function or how long they live. A registered trial combining urolithin A and fisetin is one of the first attempts to test compounds from these two categories together.
Oral bioavailability under ten percent turns a 500 milligram capsule into something closer to 50 milligrams in circulation, which is the whole argument.
Novermix
Why the dose arithmetic matters more than the mechanism
Fisetin is poorly soluble and heavily metabolised on first pass. Published estimates of oral bioavailability commonly sit under ten percent. Run that through a standard 500 milligram capsule and roughly 50 milligrams reaches circulation, well below the tissue concentrations that produced senescent cell clearance in research settings.
That gap explains a lot of the product churn in this category. Brands have moved toward liposomal preparations, phospholipid complexes, and piperine or phytosome pairings, all of which are attempts to solve the same problem. Some of those formats have absorption data behind them. Many do not.
It also explains why continuous low-dose fisetin is a different product from the intermittent high-dose protocols used in research. A daily low dose may have antioxidant and anti-inflammatory activity. Calling it a senolytic at that level is a marketing decision, not a pharmacological one.
What to ask before buying
Ask what the absorption claim is based on. A liposomal label with no supporting pharmacokinetic data is a shape, not a result. Ask whether the product is standardised, and to what. Ask whether the dosing schedule on the bottle resembles anything used in a study.
And take seriously that this is a category where the honest answer to 'is it working' is that you cannot tell. Any product sold on the promise of a noticeable effect from senolysis is overselling.
Formats you will see on the shelf
Cheapest and most common. At doses under 500 milligrams per day, the effective systemic dose is small enough that senolytic framing is difficult to defend.
Encapsulation or phospholipid complexing intended to improve absorption. The concept is sound. Whether a specific product achieves it depends on data that most brands do not publish.
Fisetin paired with quercetin, urolithin A, or a NAD+ precursor. Convenient, but each addition makes it harder to attribute any effect, and doses of the individual components are often below what was trialled.
Common questions
Is fisetin the same as quercetin?
They are related flavonoids with overlapping activity, and both appear in senolytic research. They are not interchangeable, and the dasatinib and quercetin combination used in clinical research is a prescription protocol, not a supplement.
Should someone under 40 take it?
Senescent cell burden becomes a meaningful factor later in life, so the argument for early use is weak. There is no evidence supporting preventive use in young adults.
How would I know it is doing anything?
You would not, from how you feel. Research uses inflammatory and senescence markers measured over months. That is not something a consumer can replicate.
Sources
- Natural bioactive compounds targeting key hallmarks of aging — https://www.mdpi.com/2072-6643/18/15/2511
- Bioactive compounds and functional foods review (PMC) — https://pmc.ncbi.nlm.nih.gov/articles/PMC13468152/